TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2126633

Group type: EXPERIMENTAL
Intervention: 20 Gy
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: 22 Gy
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: 20/20.4 Gy
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: 18 Gy
Number of subjects: 550

Group type: EXPERIMENTAL
Intervention: 16 Gy
Number of subjects: 550
Study: 7436690

Group type: EXPERIMENTAL
Intervention: Clomipramine hydrochloride
Number of subjects: 22

Group type: COMPARATOR
Intervention: Nortriptyline hydrochloride
Number of subjects: 22

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study: 31855924

Group type: EXPERIMENTAL
Intervention: Foot massage
Number of subjects: 196

Group type: EXPERIMENTAL
Intervention: Hand massage
Number of subjects: 196

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 196
Study: 30153580

Group type: EXPERIMENTAL
Intervention: Phosphorus (500 mg) with a high-carbohydrate meal
Number of subjects: 15

Group type: COMPARATOR
Intervention: Placebo with a high-carbohydrate meal
Number of subjects: 15
Study: 28500089

Group type: EXPERIMENTAL
Intervention: Manchester Acute Coronary Syndromes (MACS) decision rule
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 10
Study: 26059086

Group type: EXPERIMENTAL
Intervention: InCARE intervention for informal caregivers
Number of subjects: 198
Study: 22405094

Group type: EXPERIMENTAL
Intervention: Hyaluronic acid gauze pad
Number of subjects: 89

Group type: COMPARATOR
Intervention: Neutral vehicle
Number of subjects: 89
Study: 21098520

Group type: EXPERIMENTAL
Intervention: Acetaminophen
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acetaminophen plus codeine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ibuprofen plus midazolam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (Acetaminophen alone)
Number of subjects: 0
Study: 19196729

Group type: EXPERIMENTAL
Intervention: SubRPE (5000 m at a constant rating of perceived exertion RPE 15-Hard)
Number of subjects: 9

Group type: COMPARATOR
Intervention: SubEXT (5000 m at an enforced constant pace equivalent to the mean power output of SubRPE)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: MaxTT (maximal condition included for randomization)
Number of subjects: 9
Study: 16979855

Group type: EXPERIMENTAL
Intervention: Blood sampling from the forearm using the Free Style device
Number of subjects: 60

Group type: COMPARATOR
Intervention: Conventional blood sampling from the heel using a lancet
Number of subjects: 60
Study: 14998609

Group type: EXPERIMENTAL
Intervention: Coronary artery stenting
Number of subjects: 611

Group type: COMPARATOR
Intervention: PTCA (balloon angioplasty)
Number of subjects: 611
Study: 9418710

Group type: EXPERIMENTAL
Intervention: Preimplantation genetic diagnosis for aneuploidy
Number of subjects: 28

Group type: COMPARATOR
Intervention: Assisted zona hatching
Number of subjects: 28
Study: 8494378

Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 9

Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 9
Study: 3806894

Group type: EXPERIMENTAL
Intervention: Intradermal human diploid cell rabies vaccine (ID HDCV)
Number of subjects: 124
Study: 29241421

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (220 mg zinc sulfate capsules every 72 hours for 1 month)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Zinc supplementation
Number of subjects: 54
Study: 25846071

Group type: EXPERIMENTAL
Intervention: Bifidobacterium longum BB536 (BB536) supplementation
Number of subjects: 300

Group type: COMPARATOR
Intervention: Control (no supplementation)
Number of subjects: 300
Study: 24937077

Group type: EXPERIMENTAL
Intervention: Smoking prevention program 'ohnekippe'
Number of subjects: 1427

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1427

Group type: EXPERIMENTAL
Intervention: Modified smoking prevention program 'ohnekippe'
Number of subjects: 1427

Group type: EXPERIMENTAL
Intervention: Overall smoking prevalence in the catchment area
Number of subjects: 1427
Study: 22752567

Group type: EXPERIMENTAL
Intervention: Lenalidomide plus dexamethasone
Number of subjects: 704

Group type: COMPARATOR
Intervention: Placebo plus dexamethasone
Number of subjects: 704
Study: 20705223

Group type: EXPERIMENTAL
Intervention: Weight gain (approximately 4 kg) over 8 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Weight maintenance (no weight gain)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Weight loss after fat gain
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Visceral fat gain
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Subcutaneous fat gain
Number of subjects: 43
Study: 18644682

Group type: EXPERIMENTAL
Intervention: Anonymous questionnaire + BPL
Number of subjects: 801

Group type: EXPERIMENTAL
Intervention: Named questionnaire + BPL
Number of subjects: 801

Group type: COMPARATOR
Intervention: Anonymous questionnaire without BPL
Number of subjects: 801

Group type: COMPARATOR
Intervention: Named questionnaire without BPL
Number of subjects: 801
Study: 15958805

Group type: EXPERIMENTAL
Intervention: 0.5 mg of MLN02 per kilogram
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: 2.0 mg of MLN02 per kilogram
Number of subjects: 181

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 181
Study: 12210871

Group type: EXPERIMENTAL
Intervention: Unified Parkinson's Disease Rating Scale (UPDRS)
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Derived symptom-based scales
Number of subjects: 400

Group type: EXPERIMENTAL
Intervention: Testing interval within 14 days
Number of subjects: 400
Study: 10325259

Group type: EXPERIMENTAL
Intervention: Percutaneous oestradiol 0.1 mg/day from day 10 after the LH surge until day 4 of the following cycle
Number of subjects: 6

Group type: COMPARATOR
Intervention: Control cycle
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Percutaneous oestradiol 0.1 mg/day
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 6
Study: 7758304

Group type: EXPERIMENTAL
Intervention: Carbopol gel with 10% CaNa2-EDTA
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Carbopol gel without CaNa2-EDTA
Number of subjects: 21

Group type: COMPARATOR
Intervention: Nickel alloy without barrier gel
Number of subjects: 21
Study: 1955506

Group type: EXPERIMENTAL
Intervention: Al(OH)3
Number of subjects: 14
Study: 7141605

Group type: EXPERIMENTAL
Intervention: Moderate dietary salt restriction
Number of subjects: 25
Study: 6390659

Group type: EXPERIMENTAL
Intervention: Ketotifen 0.5 mg X 2 daily
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Ketotifen 1 mg X 2 daily
Number of subjects: 260

Group type: COMPARATOR
Intervention: Clemastine fumarate 1.34 mg X 2 daily
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo for ketotifen
Number of subjects: 260

Group type: COMPARATOR
Intervention: Placebo for clemastine
Number of subjects: 260
Study: 29775083

Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg IV every 8 h plus enteral nutrition (EN)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Enteral nutrition (EN) alone
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Ranitidine 50 mg IV every 8 h plus EN
Number of subjects: 2
Study: 27107849

Group type: EXPERIMENTAL
Intervention: Alcohol cessation
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 22
Study: 24140383

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (300,000 IU)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 22669346

Group type: EXPERIMENTAL
Intervention: FM algorithm
Number of subjects: 48

Group type: COMPARATOR
Intervention: VA algorithm
Number of subjects: 48
Study: 20220044

Group type: EXPERIMENTAL
Intervention: CP‐642,931 (35 mg daily for 7 days)
Number of subjects: 57
Study: 18559904

Group type: EXPERIMENTAL
Intervention: Expert radiologists scoring of parametric images
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Novice radiologists scoring of parametric images
Number of subjects: 21
Study: 16499109

Group type: EXPERIMENTAL
Intervention: Clonidine
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard anesthesia (Control)
Number of subjects: 96
Study: 11998711

Group type: EXPERIMENTAL
Intervention: Extended arterial revascularisation
Number of subjects: 30
Study: 10048793

Group type: EXPERIMENTAL
Intervention: Inulin
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Galacto‐oligosaccharides (GOS)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fructo‐oligosaccharides (FOS)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Control
Number of subjects: 12
Study: 7729018

Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG) surgery
Number of subjects: 1484

Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 1484

Group type: EXPERIMENTAL
Intervention: CABG surgery in patients with normal LV systolic function
Number of subjects: 1484

Group type: COMPARATOR
Intervention: Medical therapy in patients with normal LV systolic function
Number of subjects: 1484

Group type: EXPERIMENTAL
Intervention: CABG surgery in patients with normal LV systolic function and right coronary artery stenosis > or = 70%
Number of subjects: 1484

Group type: COMPARATOR
Intervention: Medical therapy in patients with normal LV systolic function and right coronary artery stenosis > or = 70%
Number of subjects: 1484
Study: 2372155

Group type: EXPERIMENTAL
Intervention: 4 ml of 0.5% bupivacaine injected (1 ml every 10 seconds) for spinal anesthesia in group 1 (n = 16)
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: 2 ml of 0.5% bupivacaine injected for continuous spinal anesthesia in group 2 (n = 18)
Number of subjects: 34
Study: 7272174

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 15 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 30 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 60 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 120 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) single doses
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) chronic dosing
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN) 60 mg single dose
Number of subjects: 12
Study: 31723985

Group type: EXPERIMENTAL
Intervention: Post-transplantation cyclophosphamide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 29340317

Group type: EXPERIMENTAL
Intervention: Cognitive Training (CT)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Exercise Training (ET)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Standard of Care (SC)
Number of subjects: 20
Study: 26743431

Group type: EXPERIMENTAL
Intervention: Artesunate‐amodiaquine (ASAQ)
Number of subjects: 857

Group type: EXPERIMENTAL
Intervention: Artemether‐lumefantrine (AL)
Number of subjects: 857
Study: 23475983

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg EOW
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 23983351

Group type: EXPERIMENTAL
Intervention: IMUNITI (herbal product with immune-modulating properties)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 48
Study: 20919773

Group type: EXPERIMENTAL
Intervention: Stereotype threat (ST)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stereotype threat (ST) during learning modular arithmetic (MA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 17386059

Group type: EXPERIMENTAL
Intervention: 4:1 ketogenic diet
Number of subjects: 76

Group type: COMPARATOR
Intervention: 3:1 ketogenic diet
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: 4:1 ketogenic diet to 3:1 diet
Number of subjects: 76

Group type: COMPARATOR
Intervention: 3:1 ketogenic diet to 4:1 diet
Number of subjects: 76
Study: 16155693

Group type: EXPERIMENTAL
Intervention: Full-mouth scaling and root planning (FM-SRP)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Quadrant scaling and root planning (Q-SRP)
Number of subjects: 60
Study: 11280495

Group type: COMPARATOR
Intervention: Icodextrin-based PD fluids
Number of subjects: 24

Group type: COMPARATOR
Intervention: Glucose-based PD fluids
Number of subjects: 24
Study: 9374560

Group type: EXPERIMENTAL
Intervention: 1500 mg/kg of RSVIG (RespiGam, MedImmune Inc, Gaithersburg, MD)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Albumin placebo
Number of subjects: 101
Study: 8193609

Group type: EXPERIMENTAL
Intervention: Cilazapril 2.5 mg once daily (increased to 5.0 mg if necessary)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Captopril 25 mg twice daily (increased to 50 mg if necessary)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Cilazapril with adjunctive hydrochlorothiazide (12.5 mg once daily)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Captopril with adjunctive hydrochlorothiazide (12.5 mg once daily)
Number of subjects: 132
Study: 3250578

Group type: EXPERIMENTAL
Intervention: RestoreTM Wound Care Dressing (test dressing)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Duoderm (control dressing)
Number of subjects: 0
Study: 29992353

Group type: EXPERIMENTAL
Intervention: REThink intervention
Number of subjects: 165

Group type: COMPARATOR
Intervention: Rational Emotive Behavior Education condition
Number of subjects: 165

Group type: COMPARATOR
Intervention: Waitlist condition
Number of subjects: 165
Study: 28569519

Group type: EXPERIMENTAL
Intervention: Varenicline plus smoking cessation counseling and prolonged exposure therapy (VARCC + PE)
Number of subjects: 142

Group type: COMPARATOR
Intervention: Varenicline plus smoking cessation counseling (VARCC)
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy (PE)
Number of subjects: 142
Study: 26385452

Group type: EXPERIMENTAL
Intervention: Worsened or incomplete ST-segment depression resolution (STD-R)
Number of subjects: 611

Group type: COMPARATOR
Intervention: Complete ST-segment depression resolution (STD-R)
Number of subjects: 611
Study: 23614971

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125%
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.125% and fentanyl 2 μg/mL
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.1% plus fentanyl 2 μg/mL and epinephrine 2 μg/mL
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 28
Study: 21883698

Group type: EXPERIMENTAL
Intervention: Capsaicin (0.75 mg)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 73
Study: 18188511

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal controls
Number of subjects: 40
Study: 16769782

Group type: EXPERIMENTAL
Intervention: Intra-articular glucocorticoid treatment with 20 mg triamcinolone hexacetonide (THA) and 24 hour bed rest
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intra-articular glucocorticoid treatment with 20 mg triamcinolone hexacetonide (THA) and normal activity
Number of subjects: 20
Study: 15229016

Group type: EXPERIMENTAL
Intervention: Medical abortion treatment
Number of subjects: 44789

Group type: EXPERIMENTAL
Intervention: Pretreatment screening methods
Number of subjects: 44789
Study: 11466259

Group type: EXPERIMENTAL
Intervention: 0.005% latanoprost once daily
Number of subjects: 1256

Group type: COMPARATOR
Intervention: 0.5% timolol twice daily
Number of subjects: 1256
Study: 9383230

Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV) at 6, 8 and 14 months after BMT (early group, n = 23)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Inactivated poliovirus vaccine (IPV) at 18, 20 and 26 months after BMT (late group, n = 22)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Inactivated poliovirus vaccine (IPV)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Acute GVHD
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Chronic GVHD
Number of subjects: 45
Study: 8256243

Group type: EXPERIMENTAL
Intervention: Beclomethasone dipropionate (2 mg/day for five months, then 1 mg/day for three months)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Budesonide (1.6 mg/day for five months, then 0.8 mg/day for three months)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 15
Study: 2863224

Group type: EXPERIMENTAL
Intervention: Combined H1- and H2-receptor antagonists (clemastine and cimetidine)
Number of subjects: 800

Group type: COMPARATOR
Intervention: 0.9% saline (control group)
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Intravenous prednisolone
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: H1-antagonist clemastine
Number of subjects: 800
Study: 31409286

Group type: EXPERIMENTAL
Intervention: Text message-based intervention promoting breastfeeding and appropriate complementary feeding (18 messages over 4 months)
Number of subjects: 80
Study: 27893535

Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU)
Number of subjects: 379

Group type: COMPARATOR
Intervention: gemcitabine (GEM)
Number of subjects: 379
Study: 26540732

Group type: EXPERIMENTAL
Intervention: Intravenous high‐dose methylprednisolone treatment
Number of subjects: 48

Group type: COMPARATOR
Intervention: Oral high‐dose methylprednisolone treatment
Number of subjects: 48
Study: 24629554

Group type: EXPERIMENTAL
Intervention: Self-reported activity (MVPA-SR) in KAM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Self-reported activity (MVPA-SR) in KIO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accelerometry (MVPA-A) in KAM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Accelerometry (MVPA-A) in KIO
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Correlation between MVPA-A and MVPA-SR in KIO
Number of subjects: 0
Study: 22617366

Group type: EXPERIMENTAL
Intervention: Short nurse-based group education
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long multidisciplinary group education
Number of subjects: 0
Study: 20624187

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT) group
Number of subjects: 4

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 4
Study: 18698064

Group type: EXPERIMENTAL
Intervention: School-based group intervention (15 sessions over 5 weeks) including trauma-processing activities, cooperative play, and creative-expressive elements.
Number of subjects: 495

Group type: COMPARATOR
Intervention: Wait-listed control group
Number of subjects: 495
Study: 15718838

Group type: EXPERIMENTAL
Intervention: Vaccination with ALVAC‐HIV (vCP1433) and Lipo‐6T vaccines followed by subcutaneous interleukin‐2 (weeks 16, 24, 32)
Number of subjects: 71

Group type: COMPARATOR
Intervention: Antiviral therapy alone (control)
Number of subjects: 71
Study: 12795341

Group type: EXPERIMENTAL
Intervention: Seratrodast
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Pranlukast
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 10695098

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg daily for 4 weeks followed by prophylaxis for 24 weeks
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study: 9772586

Group type: EXPERIMENTAL
Intervention: Shexiang Baoxinwan (SXBXW)
Number of subjects: 210

Group type: COMPARATOR
Intervention: Isosorbide dinitrate
Number of subjects: 210
Study: 8457027

Group type: EXPERIMENTAL
Intervention: Hypnotic suggestions to increase reaction to DCP and decrease reaction to DNCB
Number of subjects: 16

Group type: COMPARATOR
Intervention: Hypnotic suggestions to decrease reaction to DCP and increase reaction to DNCB
Number of subjects: 16
Study: 3026010

Group type: EXPERIMENTAL
Intervention: Sulbactam/ampicillin plus probenecid (1 g probenecid orally and either one vial of sodium sulbactam/ampicillin or two vials intramuscularly; each vial contained 0.5 g of sodium sulbactam and 1 g of sodium ampicillin)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Sulbactam/ampicillin (two vials intramuscularly)
Number of subjects: 45
Study: 31687769

Group type: EXPERIMENTAL
Intervention: Smoking cessation intervention
Number of subjects: 202

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 202
Study: 28629269

Group type: EXPERIMENTAL
Intervention: Obstacle aquatic therapy
Number of subjects: 46

Group type: COMPARATOR
Intervention: Traditional aquatic therapy
Number of subjects: 46
Study: 27054424

Group type: EXPERIMENTAL
Intervention: Transposed flap procedure (n=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Repositioned flap procedure (n=12)
Number of subjects: 24
Study: 23375352

Group type: EXPERIMENTAL
Intervention: 1.2 mL 2% lidocaine infused 3 min prior to IUD insertion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Normal saline infused 3 min prior to IUD insertion
Number of subjects: 40
Study: 21417983

Group type: EXPERIMENTAL
Intervention: Scapular manipulation
Number of subjects: 61

Group type: COMPARATOR
Intervention: Kocher's method
Number of subjects: 61
Study: 18521540

Group type: EXPERIMENTAL
Intervention: AGI-1067 (300 mg daily for 12 weeks)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 229
Study: 17907712

Group type: EXPERIMENTAL
Intervention: Staged-based, computerized smoking cessation intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 0
Study: 15203800

Group type: EXPERIMENTAL
Intervention: Counseling and nicotine gum for smoking cessation
Number of subjects: 1722
Study: 11237499

Group type: EXPERIMENTAL
Intervention: Intra-arterial (i.a.) cisplatinum (CDP) in three-drug regimen
Number of subjects: 221

Group type: COMPARATOR
Intervention: Intravenous (i.v.) cisplatinum (CDP) in three-drug regimen
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Four-drug regimen (HDMTX, ADM, IFO) with i.a. CDP
Number of subjects: 221

Group type: COMPARATOR
Intervention: Four-drug regimen (HDMTX, ADM, IFO) with i.v. CDP
Number of subjects: 221

Group type: EXPERIMENTAL
Intervention: Comparison of limb salvage, local recurrence, and event-free survival (EFS) between i.a. and i.v. groups
Number of subjects: 221
Study: 9433629

Group type: EXPERIMENTAL
Intervention: New statistical test for comparing mean age of onset in parents with mean age of onset in children.
Number of subjects: 0
Study: 8292844

Group type: EXPERIMENTAL
Intervention: Human growth hormone
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Growth hormone releasing hormone
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 2873132

Group type: EXPERIMENTAL
Intervention: Estazolam
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 65

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65